These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 21673063)

  • 1. Multihistology, target-driven pilot trial of oral topotecan as an inhibitor of hypoxia-inducible factor-1α in advanced solid tumors.
    Kummar S; Raffeld M; Juwara L; Horneffer Y; Strassberger A; Allen D; Steinberg SM; Rapisarda A; Spencer SD; Figg WD; Chen X; Turkbey IB; Choyke P; Murgo AJ; Doroshow JH; Melillo G
    Clin Cancer Res; 2011 Aug; 17(15):5123-31. PubMed ID: 21673063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pilot trial of EZN-2968, an antisense oligonucleotide inhibitor of hypoxia-inducible factor-1 alpha (HIF-1α), in patients with refractory solid tumors.
    Jeong W; Rapisarda A; Park SR; Kinders RJ; Chen A; Melillo G; Turkbey B; Steinberg SM; Choyke P; Doroshow JH; Kummar S
    Cancer Chemother Pharmacol; 2014 Feb; 73(2):343-8. PubMed ID: 24292632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topotecan inhibits vascular endothelial growth factor production and angiogenic activity induced by hypoxia in human neuroblastoma by targeting hypoxia-inducible factor-1alpha and -2alpha.
    Puppo M; Battaglia F; Ottaviano C; Delfino S; Ribatti D; Varesio L; Bosco MC
    Mol Cancer Ther; 2008 Jul; 7(7):1974-84. PubMed ID: 18645007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Schedule-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts.
    Rapisarda A; Zalek J; Hollingshead M; Braunschweig T; Uranchimeg B; Bonomi CA; Borgel SD; Carter JP; Hewitt SM; Shoemaker RH; Melillo G
    Cancer Res; 2004 Oct; 64(19):6845-8. PubMed ID: 15466170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas.
    Kummar S; Chen A; Ji J; Zhang Y; Reid JM; Ames M; Jia L; Weil M; Speranza G; Murgo AJ; Kinders R; Wang L; Parchment RE; Carter J; Stotler H; Rubinstein L; Hollingshead M; Melillo G; Pommier Y; Bonner W; Tomaszewski JE; Doroshow JH
    Cancer Res; 2011 Sep; 71(17):5626-34. PubMed ID: 21795476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIF-1alpha modulation by topoisomerase inhibitors in non-small cell lung cancer cell lines.
    Choi YJ; Rho JK; Lee SJ; Jang WS; Lee SS; Kim CH; Lee JC
    J Cancer Res Clin Oncol; 2009 Aug; 135(8):1047-53. PubMed ID: 19148680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIF-1α activation mediates resistance to anti-angiogenic therapy in neuroblastoma xenografts.
    Hartwich J; Orr WS; Ng CY; Spence Y; Morton C; Davidoff AM
    J Pediatr Surg; 2013 Jan; 48(1):39-46. PubMed ID: 23331791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition.
    Rapisarda A; Hollingshead M; Uranchimeg B; Bonomi CA; Borgel SD; Carter JP; Gehrs B; Raffeld M; Kinders RJ; Parchment R; Anver MR; Shoemaker RH; Melillo G
    Mol Cancer Ther; 2009 Jul; 8(7):1867-77. PubMed ID: 19584228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitors of HIF-1α and CXCR4 Mitigate the Development of Radiation Necrosis in Mouse Brain.
    Yang R; Duan C; Yuan L; Engelbach JA; Tsien CI; Beeman SC; Perez-Torres CJ; Ge X; Rich KM; Ackerman JJH; Garbow JR
    Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):1016-1025. PubMed ID: 29485043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Weekly EZN-2208 (PEGylated SN-38) in combination with bevacizumab in patients with refractory solid tumors.
    Jeong W; Park SR; Rapisarda A; Fer N; Kinders RJ; Chen A; Melillo G; Turkbey B; Steinberg SM; Choyke P; Doroshow JH; Kummar S
    Invest New Drugs; 2014 Apr; 32(2):340-6. PubMed ID: 24242862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topotecan blocks hypoxia-inducible factor-1alpha and vascular endothelial growth factor expression induced by insulin-like growth factor-I in neuroblastoma cells.
    Beppu K; Nakamura K; Linehan WM; Rapisarda A; Thiele CJ
    Cancer Res; 2005 Jun; 65(11):4775-81. PubMed ID: 15930297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
    Gerrits CJ; Burris H; Schellens JH; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Fields S; Von Hoff DD; Verweij J
    Clin Cancer Res; 1998 May; 4(5):1153-8. PubMed ID: 9607572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I clinical trial of the mammalian target of rapamycin inhibitor everolimus in combination with oral topotecan for recurrent and advanced endometrial cancer.
    Acevedo-Gadea C; Santin AD; Higgins SA; Urva S; Ratner E; Silasi DA; Azodi M; Rutherford T; Schwartz PE; Abu-Khalaf MM
    Int J Gynecol Cancer; 2014 Mar; 24(3):528-33. PubMed ID: 24557436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lenticular cytoprotection. Part 1: the role of hypoxia inducible factors-1α and -2α and vascular endothelial growth factor in lens epithelial cell survival in hypoxia.
    Neelam S; Brooks MM; Cammarata PR
    Mol Vis; 2013; 19():1-15. PubMed ID: 23335846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II and pharmacokinetic/pharmacodynamic trial of sequential topoisomerase I and II inhibition with topotecan and etoposide in advanced non-small-cell lung cancer.
    Dowlati A; Levitan N; Gordon NH; Hoppel CL; Gosky DM; Remick SC; Ingalls ST; Berger SJ; Berger NA
    Cancer Chemother Pharmacol; 2001; 47(2):141-8. PubMed ID: 11269740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anticancer imidazoacridinone C-1311 inhibits hypoxia-inducible factor-1α (HIF-1α), vascular endothelial growth factor (VEGF) and angiogenesis.
    Paradziej-Łukowicz J; Skwarska A; Peszyńska-Sularz G; Brillowska-Dąbrowska A; Konopa J
    Cancer Biol Ther; 2011 Oct; 12(7):586-97. PubMed ID: 21775820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cell type-specific, topoisomerase II-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation by NSC 644221.
    Creighton-Gutteridge M; Cardellina JH; Stephen AG; Rapisarda A; Uranchimeg B; Hite K; Denny WA; Shoemaker RH; Melillo G
    Clin Cancer Res; 2007 Feb; 13(3):1010-8. PubMed ID: 17289897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. UVC inhibits HIF-1alpha protein translation by a DNA damage- and topoisomerase I-independent pathway.
    Rapisarda A; Melillo G
    Oncogene; 2007 Oct; 26(48):6875-84. PubMed ID: 17496931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin).
    Gerrits CJ; Schellens JH; Burris H; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Von Hoff DD; Verweij J
    Clin Cancer Res; 1999 Jan; 5(1):69-75. PubMed ID: 9918204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current insights and future perspectives of hypoxia-inducible factor-targeted therapy in cancer.
    Ajith TA
    J Basic Clin Physiol Pharmacol; 2018 Dec; 30(1):11-18. PubMed ID: 30260792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.